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Leukocyte telomere length and serum
polyunsaturated fatty acids, dietary habits,
cardiovascular risk factors and features of
myocardial infarction in elderly patients
Are A. Kalstad1,2* , Sjur Tveit2,3, Peder L. Myhre3, Kristian Laake1, Trine B. Opstad1,2, Arnljot Tveit2,4, Erik B. Schmidt5,
Svein Solheim1, Harald Arnesen1,2 and Ingebjørg Seljeflot1,2
Abstract
Background: Telomeres are non-coding sequences at the end of eukaryote chromosomes, which in complex
with associated proteins serve to protect subtelomeric DNA. Telomeres shorten with each cell division, are regarded
as a biomarker for aging and have also been suggested to play a role in atherosclerosis and cardiovascular disease
(CVD). The aim of the present study was to explore the associations between leukocyte telomere length and serum
polyunsaturated fatty acids, diet, cardiovascular risk factors and features of myocardial infarction (MI) in elderly
patients.
Methods: The material is based upon the first 299 included patients in the OMEMI trial, where patients aged 70–82
years of age are randomized to receive omega-3 supplements or corn oil (placebo) after MI. Patients were included
2–8 weeks after the index MI. DNA was extracted from whole blood, and leukocyte telomere length (LTL) was
analyzed by qPCR and reported as a number relative to a reference gene. Serum long chain polyunsaturated fatty
acid (LCPUFA) content was analyzed by gas chromatography. Diet was evaluated with the validated SmartDiet food
frequency questionnaire. Medical records, patient interviews and clinical examination provided previous medical
history and anthropometric data. Non-parametric statistical tests were used.
Results: Median (25, 75 percentile) LTL was 0.55 (0.42, 0.72). Patients had a median age of 75 years, 70.2% were
male and 45.2% used omega-3 supplements. There was a weak, but significant correlation between LTL and linoleic
acid (r = 0.139, p = 0.017), but not with other LCPUFAs. There was a trend towards longer telomeres with a healthier
diet, but this did not reach statistical significance (p = 0.073). No associations were found between LTL and CVD risk
factors or features of MI.
Conclusions: In our population of elderly with a recent myocardial infarction LTL was associated with linoleic acid
concentrations, but not with other LCPUFAs. Patients with a healthy diet tended to have longer telomeres. The
limited associations may be due to age and the narrow age-span in our population. Further studies, designed to
detect longitudinal changes should be performed to explore the role of telomeres in cardiovascular aging.
Trial registration: Clinical trials no. NCT01841944, registration date April 29, 2013.
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Background
Age is the most important risk factor for cardiovascular
disease (CVD) and the prevalence of age-related diseases
is increasing with the general ageing of the population
[1]. Several molecular pathways of ageing related to
CVD have been suggested, including oxidative stress, in-
flammation and remodeling [2–4]. Lately, there has been
great interest in the importance of telomeres and their
shortening [5, 6] both as related to the ageing process
and their role in CVD.
Telomeres are repeating hexameric segments (TTAG
GG) of DNA and associated proteins, and form the ends
of chromosomes of eukaryotic cells. They play an im-
portant role in stabilizing the chromosome and protect
the ends against degradation or end-to-end fusion dur-
ing DNA damage and repair. As DNA polymerase is un-
able to replicate the ends of chromosomes, their length
is shortened with each cell division. The telomere loss
over time is age-dependent in humans [7], ranging 30–
200 base pairs per cell cycle [8]. After reaching a certain
length, the cells cease to divide, leading to cellular senes-
cence [9]. Telomere shortening is counteracted by the
enzyme telomerase, which has the capability to elongate
telomeres [10]. In addition, telomere shortening has
been shown to be influenced by modifiable factors such
as lifestyle and environmental risk factors [11, 12].
Leukocyte telomere length (LTL) and their attrition rate
have been associated with different markers of athero-
sclerosis in some studies [6, 13–15], while others have
demonstrated more ambiguous results [16, 17]. Add-
itionally, a relationship between telomere length and
myocardial infarction (MI) has been reported [18, 19].
Long chain polyunsaturated fatty acids (LCPUFA) have
been proposed to influence LTL, possibly through effects
on oxidative stress and telomerase activity [20]. An obser-
vational study by Farzaneh-Far R et al. [21] demonstrated
a significant reduced shortening with higher baseline
levels of eicoapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) over a period of 6 years in a CVD population
[21]. Reduced shortening of telomeres was also reported
with decreasing n-6/n-3 ratio in a supplementation study
in a healthy middle-aged population [22].
The aim of the present study was to further explore
the relationship between LTL and selected commonly
studied LCPUFAs and diet in elderly survivors of myo-
cardial infarction (MI). In addition, any associations of
LTL with risk cardiovascular risk factors, MI characteris-
tics and markers of myocardial injury and dysfunction
were explored.
Material and methods
Study design
This paper presents a cross-sectional substudy of data
obtained at time of inclusion in the ongoing OMega-3
fatty acids in Elderly patients with Myocardial Infarction
(OMEMI) trial [23], in which elderly survivors of AMI
are randomized to 2 years intervention with either 1.8 g
marine n-3 fatty acids in the form of Pikasol capsules
(Axellus AS, Oslo/Orkla Health, Norway) or corn oil
placebo. The present investigation was performed in the
first 299 consecutively enrolled patients.
The project was performed in accordance with the
Declaration of Helsinki, approved by the Regional Ethical
Committee South East with (Reference no.: 2012/1422),
and registered at ClinicalTrials.gov (NCT01841944). All
patients gave written informed consent to participate.
Patient population
Patients were recruited at three hospitals in the Oslo re-
gion of Norway; the Oslo University Hospital, Ullevål,
Oslo, Vestre Viken Hospital Trust, Bærum and Akershus
University Hospital, Lørenskog. Patients were screened
during their initial hospital admission. Inclusion criteria
were patients who had undergone MI, age between 70
and 82 years, and ability to understand verbal and
written patient information in Norwegian language and
provide written consent. Exclusion criteria were docu-
mented intolerance for n-3 fatty acids, and additional
disease states thought to influence survival and/or ability
to adhere to study medication and follow up for the
study period. Previous regular intake of n-3 supplements
was not an exclusion criterion, as such intake is fairly
common in the general Norwegian population, and ex-
clusion would introduce a selection bias to the study. Pa-
tients were included two to 8 weeks after hospital
discharge. The inclusion period for the 299 patients was
November 2012 to November 2014. The study design
has previously been described in detail [23].
Previous medical history and data regarding the index
MI were retrieved from hospital records, including the
classification of the MI as ST-segment elevation MI
(STEMI) or non-ST-segment MI (NSTEMI), and peak
Troponin T levels occurring from sequential measures
during hospital stay. Echocardiography was performed
as part of the clinical management in a total of 162 pa-
tients, and left ventricular ejection fraction (LVEF) was
registered. Previous hypertension was defined as previ-
ous diagnosis of hypertension, and previous hyperlipid-
emia was defined as previous diagnosis or treatment
with lipid lowering drugs. Current smoking was defined
as current smoking or cessation no more than 3 months
prior to inclusion.
Diet registration
The patients’ diet was assessed using the SmartDiet form
which is a validated food frequency questionnaire, previ-
ously described [24]. The SmartDiet form was filled out
once, and is based on the patients’ recollection of intake
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of different food groups, with a special emphasis on fats.
Each of the items are scored, and summarized to a total
score ranging from 15 to 45 points. The scores are fur-
ther divided into three groups, where a score of 15–27 is
considered an unhealthy diet (designated poor), a score
of 28–35 a diet should be improved (designated inter-
mediate), and a score of 36–45 points is considered a
healthy diet (designated healthy). As the subdivision into
the three arbitrary categories may limit the discovery of
association, data from SmartDiet score were also ex-
plored as a continuous variable in the present study.
Laboratory analysis
Venous blood samples were drawn in fasting state be-
tween 08:00 and 11:00 at inclusion and routine labora-
tory analyses were performed by conventional methods.
Serum was prepared within 1 h by centrifugation at
2000 x g for 10 min and kept frozen at − 80 °C until ana-
lysis of the fatty acid profile. EDTA whole blood was
drawn and kept frozen at − 80 °C until DNA extraction
for LTL analysis.
Fatty acids composition in serum phospholipids was
analyzed by gas chromatography and expressed as %
weight of total fatty acids, as previously described [25].
Briefly, serum lipids were extracted according to the
Folch procedure [26]. The organic phase containing total
lipids was collected and another extraction was per-
formed. Separation of the phospholipid fatty acid frac-
tion from total lipids was performed as described by
Burdge et al. [27]. Methylation of the fatty acids was per-
formed before being analyzed by gas chromatography
using a Varian 3900 gas chromatograph equipped with a
CP-8400 autosampler, a flame ionization detector and a
high-polarity polyester CP-Sil 88 60m × 0.25 mm capil-
lary column (Varian, Middleburg, The Netherlands).
The content expressed as % weight of serum phospho-
lipids of the LCPUFAs linoleic acid (LA) 18:2 n-6, ara-
chidonic acid (AA) 20:3 n-3, alpha-linolenic acid (ALA)
18:3 n-3, eicosapentaenoic acid (EPA) 20:5 n-3 and doc-
osahexaenoic acid (DHA) 22:6 n-3 and the ratio of the
n-6 to n-3 LCPUFAs were used for the present study, as
well as the ratio of the selected n-6 PUFAs to the se-
lected n-3 PUFAs. These have all previously been exten-
sively studied in relation to CVD [25].
Analysis of LTL
Leukocytes are a commonly used source for analysis of
telomere length in clinical studies, as they are easily ob-
tained from the circulation, also used in our study.
These have been shown to have acceptable correlation
to telomere lengths in other tissues.
DNA was extracted from EDTA whole blood by the
same lot of the QIAamp DNA Blood Mini Kit through-
out the study (Qiagen Gmbh, Hilden, Ger) and
according to the manufacturers instruction. DNA purity
and quantity was tested on the NanoDrop, ND-1000
(Saveen Werner, Sweden) and samples were stored at −
80 °C until LTL analyses.
All DNA samples were diluted to a final concentration
of 2 ng/μL and LTL was measured by singleplex quanti-
tative real-time PCR [28]. PCR amplification was per-
formed on the VIIa7 PCR Instrument with the
QuantStudio Real-Time Software (Applied Biosystems
by Life Technologies Foster City, CA, USA),using
telomere-specific primers (Invitrogen by Thermo Fisher
Scientific, Waltham, MA, US) (Additional file 1: Table
S1) and GoTaq®qPCR Master Mix (Promega, Madison,
WI, US). LTL was relatively quantified (RQ) to the
single-copy-gene (SCG) 36B34 (Invitrogen by Thermo
Fisher Scientific) (Additional file 1: Table S1) and to an
internal reference sample. The primers for both targets
were diluted to a final concentration of 4 pmol /μl, and
PCR conditions were as follow; an initial step at 95 °C
for 10 min followed by 40 cycles of 95 °C for 15 sek
and 60 °C for 1 min. All samples were run in tripli-
cates [28].. Amplification efficacy for both targets
were equal, and approximately 100%. Individual amp-
lification curves for all samples of both assays (LTLs
and SCG) were carefully validated. Technical repli-
cates with a standard deviation (SD) exceeding 0.5 Ct
or outliers, if diversely to the other replicates were
excluded from the analysis. A template negative con-
trol was included in each run. The intra- and inter
assay coefficient of variation (CV) for the LTL Ct
values were; 0.37 and 2.1%, and for the SCG Ct
values 0.20 and 0.40% (based on mean CV value be-
tween replicates on 1 plate and multiple plates, re-
spectively). The inter-run CV for the T/S ratio (LTL
Ct signal divided on the CT mean of the reference
sample) was 2.09% (based on mean CV for triplicates
run on different plates). The inter-run CV for the ex-
ponentially calculated T/S ratio was 13.2%, and when
relatively calculated to the reference sample, the CV
was 13.3% (Additional file 3: Methods).
Statistical analysis
Continuous variables are presented as mean ± SD or me-
dian (25th, 75th percentiles) as appropriate. Categorical
data are presented as numbers and/or percentages. As
most data were non-normally distributed non-
parametric statistical tests were performed. Differences
between groups were examined by Kruskal-Wallis or
Mann-Whitney U test. For correlation analyses Spear-
man’s rho were used.
A p-value < 0.05 (two-tailed) was considered statisti-
cally significant. All statistical analyses were performed
using SPSS ver. 24, IBM Corporations.
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Results
Baseline characteristics of the patient cohort (n =
299) are presented in Table 1.The median age of
was 75 (72, 78) years. Males comprised 70.2% of the
population. All patients were of Caucasian ethnicity.
Other cardiovascular risk factors were prevalent,
with 60.9% diagnosed with hypertension or used
anti-hypertensive medications, 47.8% diagnosed with
hyperlipidemia or on lipid-lowering agents and 23.1%
were diagnosed with diabetes mellitus. Pre-existing
coronary artery disease was reported in 45.2% of pa-
tients prior to the index MI. A total of 40 patients
(13.4%) had diagnosis of heart failure, either preex-
isting or diagnosed during or after the index
hospitalization. LVEF < 50% was recorded in 52 pa-
tients (32.1% of 162). NSTEMIs constituted 68.6% of
cases and STEMIs the remaining 31.4%.
Leukocyte telomere length (LTL)
LTL in the total cohort ranged from 0.11 to 1.55 and
was skewed towards shorter telomeres, with a median of
0.55 (0.42, 0.72).
LTL and fatty acids
Levels of the selected LCPUFAs presented as % weight
of total serum phospholipids and the n-3/n-6 ratio in
the total population and stratified by self-reported use of
n-3 polyunsaturated fatty acid (PUFA) supplementation
are presented in Table 2. Patients who reported regular
intake of n-3 PUFA supplements (n = 135), had signifi-
cantly higher levels of both EPA and DHA than those
who did not, and also lower levels of AA (all p < 0.001).
The n-6/n-3 ratio was also lower in patients taking n-3
PUFA supplements (p < 0.001).
Levels of LTL correlated weakly, but statistically sig-
nificantly to the content of LA in serum phospholipids
(r = 0.139, p = 0.017). Neither of the remaining investi-
gated LCPUFAs, nor the n-6/n-3 ratio correlated signifi-
cantly to LTL (r ranging from − 0.107 to 0.087 and p
ranging from 0.067 to 0.958) (Table 3). Associations
were also examined for differences in fatty acids levels
across quartiles of LTL, with no significant differences
(p > 0.1) (Fig. 1). When excluding patients using n-3
supplementation, the correlation between LTL and LA
was borderline significant (r = 0.141, p = 0.074) (Add-
itional file 2: Table S2), whereas the differences across
quartiles of LTL did not change (all p > 0.1).
LTL and diet score
The mean SmartDiet score was 29.4 (range 15, 40), with
71 (30.7%) in Group 1 (poor), 142 (61.5%) in Group 2
(intermediate) and 18 (7.8%) in Group 3 (healthy). The
respective median (25, 75%) levels of LTL were 0.55
(0.39, 0.69), 0.55 (0.43, 0.70) and 0.65 (0.45, 0.87) (Fig. 2).
Despite a trend for longer LTLs in the healthy group,
the difference did not reach statistical significance (p =
0.073). No statistically significant correlation between
LTL and score obtained by SmartDiet as a continuous
variable was observed (r = 0.043, p = 0.52).
LTL and traditional cardiovascular risk factors
LTL was not significantly correlated with age, neither for
the patient group as a whole, nor when divided by gen-
der (all p > 0.1). There were also no significant difference
between males and females, 0.55 (0.43, 0.74) vs 0.54
(0.38, 0.67) (p = 0.30).
To explore any association between LTLs and trad-
itional risk factors, levels of LTL were dichotomized
according to values below or above median level (0.55).
As show in Table 4, no significant differences were ob-
served according to values below or above median level
in number of patients with the risk factor or not.
LTL and features of myocardial infarction
Patients with STEMI had numerically longer LTL
compared to NSTEMI (0.57 (0.43, 0.75) vs 0.53 (0.42,
0.72), but not statistically significant (p = 0.89). LTLs
Table 1 Characteristics of the study cohort. Data are presented
as number (%) or median values (25, 75 percentiles)
Age (years)(range) 75 (70,82)
Males 210 (70.2)
BMI (kg/m2) 25.6 (23.8, 28.3)
Systolic BP (mmHg) 140 (125, 151)
Diastolic BP (mmHg) 74 (67, 80)
Current smokers 41 (13.7)
Previous hyperlipidemia 156 (47.8)
Previous hypertension 182 (60.9)
Diabetes mellitus 69 (23.1)
Previous chronic kidney disease1 15 (5.1)
Previous heart failure 16 (5.4)
Previous coronary artery disease 135 (45.2)
Previous ischaemic stroke 21 (7.0)
NSTEMI/STEMI 68.6 / 31.4 (205 / 94)
3-vessel disease2 61 (21.3)
Maximum Troponin T (ng/L) 700 (153, 2500)
NT-proBNP (ng/L) 634 (279, 1374)
LVEF < 50%3 52 (32.1)
Taking n-3 FA supplement 135 (45.2)
BMI Body Mass Index; NSTEMI Non-ST-segment elevation myocardial infarction;
STEMI ST-segment elevation myocardial infarction; NT-proBNP N-terminal pro-
Brain natriuretic peptide; LVEF Left ventricle ejection fraction; FA fatty acids
1creatinine > 150 μmol/L
2 of n = 286 with angiography
3 of n = 162 with echocardiography
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dichotomized by median level showed no significant dif-
ference between values below or above the median in
any marker of myocardial injury or myocardial function,
as shown in Table 4. There was also no difference in
LTL of patients presenting with heart failure at any time.
Discussion
The findings in this study of telomere lengths in elderly
patients with a recent MI were predominantly neutral. A
weak, but significant correlation between serum levels of
linoleic acid and LTL, and a borderline relationship be-
tween LTL and dietary habits were found, whereas no
significant relation to conventional cardiovascular risk
factors or features of MI could be demonstrated.
Previous studies investigating the associations between
LCPUFAs and LTL have shown that these fatty acids
affect telomere attrition rate. However, in accordance
with our findings no associations on a cross-sectional
level have been demonstrated. Farzaneh-Far et al. found
that the higher quartiles of serum EPA+ DHA were as-
sociated with reduced telomere shortening over 6 years
in patients with coronary heart disease [21]. A decreas-
ing n-6/n-3 ratio was associated with reduced shortening
in a 4 months intervention study on healthy, sedentary
overweight middle-aged and older individuals [22]. Asso-
ciations between EPA and DHA and LTL have been at-
tributed mainly to reduced oxidative stress [21, 22], but
also a possible effect on telomerase activity [20].
The positive correlation between LA and LTL levels
found in our study is, although significant, very weak. In
contrast to this finding, an inverse association between
LTL levels and LA was demonstrated, however, in a
younger female population and with LA data derived
from a dietary questionnaire [29]. It might, nevertheless,
be speculated that a mechanistic influence of PUFAs on
telomere attrition may differ across age and gender.
Although not statistically significant, a healthier diet
appeared to be associated with longer telomeres in our
study. Due to the low number of patients in the healthy
diet group, the analysis may have been underpowered to
detect a significant difference. In line with our results,
dietary fiber intake, associated with a healthy diet, has
been reported to be positively associated with LTL [29].
There is also some evidence to support that adherence
to a Mediterranean diet is associated with longer telo-
meres [12, 30, 31]. The SmartDiet score is primarily
used to explore the qualitative composition of the diet
with a focus on lipids, and cannot directly assess total
caloric intake. This may be important when discussing
possible mechanisms and impact on telomere length,
such as oxidative stress.
LTL length has been associated with atherosclerotic
disease states in several studies [32–34], however,
associations with various risk factors are less consistent
[35–37]. The most surprising finding in our study was
the lack of an association between age and LTL length
as this is firmly established in a multitude of other stud-
ies. This might be due to the narrow age span of the
population, but also to the fact that the population per
se was older. While the shortening of telomeres with age
is well-established, an attenuated telomere shortening
with older age has also been discussed [38, 39]. Another
surprising finding was the lack of gender difference,
which has been shown in several studies [38, 39]. Al-
though men and women seem to have equal telomere
lengths at birth, male telomeres have been reported to
shorten faster [40]. A general problem with studies on
telomeres in humans is that telomeres have a very large
inter-individual variation [41], and that the long life span
of humans has not yet permitted studies of the full life-
span dynamics of telomeres from birth to old age.
Table 2 Levels of selected PUFAs as % weight of total serum phospholipids, in total and according to reported intake of n-3
supplements
Total n-3 supplementation p
Yes No
Linoleic acid (LA) 18:2 n-6 19.00 ± 3.13 18.83 ± 3.02 19.16 ± 3.22 0.401
Arachidonic acid (AA) 20:3 n-3 9.65 ± 2.22 8.96 ± 1.89 10.24 ± 2.32 < 0.001
Alpha-linolenic acid (ALA) 18:3 n-3 0.23 ± .08 0.23 ± .08 0.23 ± .09 0.242
Eicosapentaenoic acid (EPA) 20:5 n-3 2.74 ± 1.38 3.20 ± 1.54 2.34 ± 1.10 < 0.001
Docosahexaenoic acid (DHA) 5.71 ± 1.43 6.31 ± 1.38 5.21 ± 1.27 < 0.001
n-6/n-3 ratio 3.64 ± 1.29 3.10 ± 1.04 4.09 ± 1.31 < 0.001
Mean ± SD are given. p-values are given for difference between n-3 supplementation or not
Table 3 Coefficients of correlations (r) between LTL and serum
phospholipid fatty acid levels
Fatty acid Spearman’s rho p
Linoleic acid (LA) 18:2 n-6 0.139 0.017
Arachidonic acid (AA) 20:3 n-3 0.014 0.812
Alpha-linolenic acid (ALA) 18:3 n-3 −0.107 0.067
Eicosapentaenoic acid (EPA) 20:5 n-3 −0.080 0.167
Docosahexaenoic acid (DHA) 22:6 n-3 0.003 0.958
n-6/n-3 ratio 0.087 0.137
Kalstad et al. BMC Geriatrics          (2019) 19:376 Page 5 of 9
We could not find any associations between LTL and
traditional cardiovascular risk factors. Such associations
have been demonstrated in some studies [35, 37, 42],
but there is no consistent pattern, and other studies have
also shown neutral results [17, 36]. Our population hav-
ing a recent MI, were heavily medicated at the time of
blood sampling, however, we do not have data on previ-
ous medication, which may have influenced the results.
Nevertheless, the lack of association between LTL and
established risk factors may be interpreted as supporting
LTL length per se as a risk factor for CVD and not act-
ing through other factors.
We could also not show any relation between LTL
and the degree of myocardial injury or function. There
are limited previous data in this regard. Studies have
associated shorter LTL with chronic heart failure [43,
44], and one study has shown poorer prognosis in
chronic heart failure with shorter LTL [45]. To our
knowledge, no report regarding LTL and heart failure in
the setting of MI in humans has been published, and
also no data on LTL and degree of myocardial necrosis.
Limitations
A significant limitation of the present study is the lack
of a control population at the same age, but free from
known CVD. Also, as mentioned, any medication used
before the index infarction, might have influenced the
results. Related to marine n-3 fatty acids, measure of tel-
omerase activity might have added to the results. Mea-
sures of myocardial injury and function were limited to
Fig. 1 Levels of the selected fatty acids (weight %) and the n-6/n-3 ratio across quartiles of LTL. LA: Linoleic acid, ALA: Alpha-linolenic acid, EPA:
Eicosapentaenoic acid, AA: Arachidonic acid DHA: Docosahexaenoic acid. All p > 0.1 (Kruskal-Wallis test for differences between quartiles)
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Fig. 2 Median LTL levels across SmartDiet score groups. Poor diet (n = 71) Score≤ 27, intermediate diet (n = 142) Score 38–35 and healthy diet
(n = 18) Score≥ 36
Table 4 Cardiovascular risk factors a) and features of myocardial infarction b) according to dichotomized LTL levels below or above
the median (0.55)
a) LTL < 0.55 LTL ≥0.55 p
Male 100 (47.8%) 109 (52.2%) 0.486
Previous hypertensiona 91 (50.3%) 90 (49.7%) 0.630
Previously hyperlipidemiab 68 (47.9%) 74 (52.1%) 0.675
Current smoker 23 (56.1%) 18 (43.9%) 0.338
Diabetes mellitus 31 (44.9%) 38 (55.1%) 0.422
Chronic kidney diseasec 9 (60.0%) 6 (40.0%) 0.381
Previous coronary artery disease 63 (47.0%) 71 (53.0%) 0.503
BMI (kg/m2) 25.8 (23.6, 28.7) 25.5 (24.0, 28.0) 0.353
b)
STEMI 41 (43.6%) 53 (56.4%) 0.194
Peak Troponin T (ng/l) 814 (146, 2355) 942 (170, 3013) 0.346
NT-proBNP (ng/l) 617 (245, 1281) 689 (321, 1431) 0.381
LVEF< 50% 54 (49.1%) 56 (50.9%) 0.637
BMI Body Mass Index; STEMI ST-segment elevation myocardial infarction; NT-proBNP N-terminal pro-Brain natriuretic peptide; LVEF Left ventricle ejection fraction
P-values refer to difference between groups with LTL below vs above median level; Pearson’s chi square or Mann-Whitney U test
a Defined as previous diagnosis of hypertension
bDefined as previous diagnosis of hyperlipidemia
cCreatinine > 150 μmol/L
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peak troponin T, NT-proBNP and LVEF by routine
echocardiography. A significant strength with regard to
the influence of LCPUFAs, however, is the individual
measurement of serum fatty acids.
Conclusion
In our study on older patients with a recent MI, no sig-
nificant associations between LTL and marine LCPUFAs
were found. However, a weak correlation to linoleic acid
was noted. Patients with a healthy diet tended to have
longer telomeres, indicating the importance of life-style
factors. The lack of associations between LTL and
traditional cardiovascular risk factors and features of
myocardial infarction might be due to the older, age-
homogeneous population. Further, especially longitu-
dinal studies are warranted.
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